Bioimaging molecular probe manufacturer Stream Bio has announced that its Conjugated Polymer Nanoparticles (CPNs) are now available to purchase worldwide through Sigma Aldrich.
Stream Bio’s CPNs have applications in diagnostics and therapeutics, with the potential to be used for imaging tumours and fluorescence-guided surgery.
Andrew Chaloner, founding director and CEO of Stream Bio, said: “We are delighted to be launching our range of CPNs with Sigma Aldrich. This has only been possible thanks to many years of hard work put in by the team here at Stream. I am excited to have our products available to a wider user base and I can’t wait to see what the future holds for our products.”
Currently, CPNs are available in four wavelengths; 475nm, 510nm, 550nm and 680nm. They can also be purchased in a conjugated form, with fluorescent streptavidin covalently attached.
Initially, a small range of unconjugated CPNs will be available to purchase from Sigma Aldrich, with a wider range of products soon to be included in the listing.
Steve Self, commercial director at Stream Bio, said: “The listing by Sigma Aldrich is an important step in terms of making our CPN technology available to a wider user base. We are excited to have many new products in the pipeline, which will broaden the application of our technology by spanning into the NIR region. In addition, a variety of new surface chemistries are also in development. We hope that this is the first of many collaborations with Sigma Aldrich and the Merck Group."